We reviewed the available literature on the efficacy of a novel anticonvulsant, Tiagabine (TGB), in the treatment of bipolar disorder. Study results indicate that TGB does not represent a valid option in acute mania due its required slow, progressive titration. More rapid titration schemes may lead to severe complications. TGB may be an option as an adjunct long-term treatment approach in refractory patients, but further studies are clearly needed to support this.
References
-
1
Meldrum B S, Chapman A G.
Basic mechanisms of gabitril (tiagabine) and future potential developments.
Epilepsia.
1999;
40
((Suppl 9))
S 2-S 6
-
2
Suzdak P D, Jansen J A.
A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor.
Epilepsia.
1995;
36
612-626
-
3
Adkins J C, Noble S.
Tiagabine a review of its pharmacodynamic and pharmacokinetic properties and terapeutic potential in the management of epilepsy.
Drugs.
1998;
55
437-460
-
4
Loiseau P.
Review of controlled trials of gabitril (tiagabine): a clinician's viewpoint.
Epilepsia.
1999;
40
((Suppl 9))
S 14-S 19
-
5
Krauss G, Carlson H A, Deaton R, Sommeville K W.
Beneficial results of tiagabine therapy in patients with psychiatric history.
Epilepsia.
1997;
37
((Suppl 8))
S 105
-
6
Leppik I E.
Tiagabine the safety landscape.
Epilepsia.
1995;
36
((Suppl 6))
S 10-S 13
-
7
Grunze H, Erfurth A, Marcuse A.
Tiagabine appears not to be efficacious in the treatment of acute mania.
Journal of Clinical Psychiatry.
1999;
60
759-762
-
8
Schaffer L C, Schaffer C B.
Tiagabine and the treatment of refractory bipolar disorder.
Am J Psychiatry.
1999;
156
2014-2015
-
9
Kaufman K R.
Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann. Clin.
Psychiatry.
1998;
10
181-184
Prof. Mauro G. Carta
Psychiatric Unit, Department of Public Health, University of Cagliari
Via Liguria 13
09127 Cagliari
Italy
Email: mgcarta@tiscalinet.it
